Edition:
India

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

15.05USD
19 Jul 2018
Change (% chg)

$-0.05 (-0.33%)
Prev Close
$15.10
Open
$15.00
Day's High
$15.30
Day's Low
$14.75
Volume
419,129
Avg. Vol
501,828
52-wk High
$27.50
52-wk Low
$8.00

Chart for

About

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company... (more)

Overall

Beta: 3.12
Market Cap(Mil.): $1,333.59
Shares Outstanding(Mil.): 83.61
Dividend: --
Yield (%): --

Financials

BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23

* SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

08 May 2018

BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

26 Apr 2018

BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

25 Apr 2018

BRIEF-Sangamo Therapeutics Files For Potential Mixed Shelf Offering

* SANGAMO THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2vH7vVF) Further company coverage:

25 Apr 2018

BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior Executive's Company Email Account

* SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE'S COMPANY EMAIL ACCOUNT

18 Apr 2018

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

22 Feb 2018

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Feb 22 Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

22 Feb 2018

BRIEF-Sangamo Therapeutics Q4 Loss Per Share $0.15

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

22 Feb 2018

BRIEF-Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer

* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER

22 Feb 2018

BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President

* SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF HEATHER D. TURNER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL Source text for Eikon: Further company coverage:

13 Feb 2018

Competitors

Earnings vs. Estimates